Back to UBS Group AG UBS Group AG

ATNMATNM
Showing 8 of 22 quarters

Position history for UBS Group AGUBS Group AG's holdings in ACTINIUM PHARMACEUTICALS INC

UBS Group AG holds 6,758 shares of ATNM (ACTINIUM PHARMACEUTICALS INC), worth $6,623 as of 2026-Q2. The position was decreased (-53.8% shares).

Current Value

$6,623

Current Shares

6,758

Total Value Change

-$62,898

Total Shares Change

-30,221

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
6,758
-53.8%
$6,6230.0%$0.98
0
2026-Q1
Increased
14,618
+151x
$14,5450.0%$1.11
20
2025-Q4
Decreased
96
-99.3%
$1310.0%$1.41
0
2025-Q3
Decreased
14,576
-43.0%
$23,3220.0%$1.62
0
2025-Q2
Decreased
25,590
-93.5%
$35,8260.0%$1.42
0
2025-Q1
Increased
396,136
+346.0%
$637,7790.0%$1.81
39
2024-Q4
Increased
88,816
+140.2%
$111,9080.0%$1.17
24
2024-Q3
Increased
36,979
+62.4%
$69,5210.0%$1.80
21

Other major holders of ATNM: BlackRock Finance, Inc., GEODE CAPITAL MANAGEMENT, LLC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used